Non-opioid Pain Treatment Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Acetaminophen, Local Anesthetics), By Pain Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

Non-opioid Pain Treatment Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Acetaminophen, Local Anesthetics), By Pain Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

Non-opioid Pain Treatment Market Growth & Trends

The global non-opioid pain treatment market size is expected to reach USD 77.91 billion by 2030, registering a CAGR of 8.3% during the forecast period, according to a new report by Grand View Research, Inc. The growth can be attributed to an increase in the prevalence of inflammatory diseases coupled with the robust product pipeline of novel non-opioid analgesics. According to the Centers for Disease Control and Prevention (CDC), around 32.5 million people are living with osteoarthritis condition in the U.S. In addition, according to the Spondylitis Association of America, about 3.2 million adult people in the U.S. have some form of Spondyloarthritis.

Initiatives are undertaken by government & nonprofit organizations to promote the usage of safer alternatives to opioids such as NSAIDs to address the increasing demand for pain relieving medicines. For instance, in February 2022, the U.S.FDA issued draft guidelines to provide recommendations to pharmaceutical companies for developing NSAIDs for the treatment of acute pain lasting for 30 days. This initiative was a part of the government’s “HHS Overdose Prevention Strategy” which focuses on the prevention, reduction, treatment, and recovery of patients from an opioid overdose. Such an initiative is projected to fuel demand for NSAID drugs over the forecast period.

Key market players are aggressively developing innovative techniques to meet the growing demand for NSAIDs for the management of pain. For instance, in June 2021, the University of Arizona developed oxytocin analogs for the treatment of patients suffering from. It is a bioavailable non-opioid pain relief product with the potential for inhaled administration. The development of such an innovative product is anticipated to drive non-opioid analgesics treatment market growth.

In September 2022, the U.S. FDA recommended avoiding non-opioid analgesics treatment in pregnancy at 20 weeks due to the high chances of kidney problems in unborn babies. Such initiatives from governments may limit the prescription of NSAIDs, thereby, restraining non-opioid pain treatment market growth.

Companies are adopting strategies such as new product development, launches, and partnerships to increase the penetration of non-opioid analgesic products. For instance, in March 2022, Vertex Pharmaceuticals announced positive results of its phase 2 clinical trial non-opioid pill that showed a significant reduction in post-operative acute pain. Successful completion of trial and subsequent approval of products is anticipated to drive non-opioid analgesics treatment market growth during the forecast period.

The market is highly competitive and the competition in the market is expected to be high during the forecast period due to the presence of a large number of players. Key companies manufacturing generic NSAID products include GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson & Johnson Services, Inc., amongst others.

Non-opioid Pain Treatment Market Report Highlights

• In 2021, the NSAIDs segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period owing to the high demand for pain treatment and the commercialization of multiple NSAIDs in recent years
• Chronic pain was the accounted for highest share in 2021. Factors such as increasing product approvals, the high incidence rate of chronic pain, and high R&D initiatives for launching innovative NSAIDs products are leading to its dominance
• Based on route of administration type, the oral segment accounted for the highest share in 2021 owing to the easy administration and wide availability of orally administered NSAIDs products in the market
• Based on the distribution channel, retail pharmacies are expected to dominate the market with a 53.98% share in 2021. This dominance can be attributed to the presence of a large number of generic NSAIDs and their easy accessibility to patients due to the large presence of retail pharmacies network
• Asia Pacific region is expected to experience the fastest growth during the forecast period owing to an increase in penetration of NSAIDs products, rise in disposable income, and high disease prevalence of inflammatory diseases in developing countries